TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04246671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAEK-VAC-HerBy
Description: TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAEK-VAC-HerBy
Description: TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAEK-VAC-HerBy
Description: TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAEK-VAC-HerBy
Description: TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAEK-VAC-HerBy
Description: TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAEK-VAC-HerBy
Description: TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).
Study: NCT01520103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorebine, Everolimus
Description: Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress

Intervention type: DRUG
Group type: OTHER
Intervention: Vinorelbine
Description: Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
Study: NCT02094885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioseal Fibrin Sealant

Intervention type: OTHER
Group type: OTHER
Intervention: Manual Compression
Study: NCT03127163

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraestromal corneal ring
Description: The patients underwent surgery to implant the intrastromal corneal ring (Ferrara Ophthalmics, Belo Horizonte, Brazil) using a manual technique. The procedures were performed by a single surgeon with extensive training in corneal surgery. All patients received the same ring, and the number (1 or 2 segments), thickness, and arc size were calculated using the nomogram provided by the manufacturer.
Study: NCT03234907

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vedolizumab placebo-matching

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vedolizumab placebo-matching

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vedolizumab placebo-matching
Study: NCT04248673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbohydrate reduced bread
Description: Consumption of carbohydrate reduced bread for three months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: carbohydrate rich bread
Description: Consumption of carbohydrate rich bread for three months.
Study: NCT04504669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8701
Description: FOXP3 antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8701
Description: FOXP3 antisense oligonucleotide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: anti PDL-1 monoclonal antibody
Study: NCT03791060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
Study: NCT03720275

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Systematic screening of TTR mutations
Description: The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
Study: NCT02822690

Intervention type: OTHER
Intervention: Hospice care at UMCG
Description: introduction of hospice care facilities on the wards at the UMCG
Study: NCT04482621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: Study duration is 6 weeks after the last dose of study drug. Number of study visits is dependent on Length of hospitalization of study participant. Study visits are scheduled on days 0-7, 11, 15, 29, and may occur via telemedicine or inpatient assessment or outpatient assessment in COVID recovered participants.~Decitabine will be administered via Intravenous Administration 10/mg/m\^2/day Dosage: 10mg/m\^2/day IV day x 5 days (1 cycle only)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline
Description: Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m\^2/day IV day x 5 days (1 cycle only)
Study: NCT02594852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: + laser
Description: Use of laser in the treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: + laser
Description: Use of laser in the treatment
Study: NCT02998125

Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Description: prospective assessments for the functional outcome before and after the total knee arthroplasty
Study: NCT03325660

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration
Description: pelvic floor exercises
Study: NCT01459848

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: block play
Description: 30 minutes of block play

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: baby dvd
Description: 30 minutes of dvd viewing
Study: NCT02723253

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement \> 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tom-OX
Description: The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
Study: NCT01877122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proflex® Mesh Mesh implantation
Description: Implantation of mesh in the incision of inguinal area

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marlex® Mesh Implant
Study: NCT01476358

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A (retinyl palmitate).
Description: Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A (retinyl palmitate).
Description: Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth
Study: NCT04550442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT01729364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crystalloid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colloid
Study: NCT02110121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosure Laser System
Description: Picosure Laser System for the Treatment of Unwanted Tattoos

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revlite Laser System
Description: Revlite Laser System for the Treatment of Unwanted Tattoos
Study: NCT02110134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revlite Laser System with hydroquinone skin care regimen
Description: Revlite Laser System with hydroquinone skin care regimen for the Treatment of Melasma

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone skin care regimen
Description: Hydroquinone skin care regimen for the Treatment of Melasma
Study: NCT01653704

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: observational role
Description: observational role in crisis scenario

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active role
Description: active role in managing crisis scenario
Study: NCT03619980

Intervention type: OTHER
Intervention: No intervention
Description: Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
Study: NCT02967926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde Cholangioscopy by SpyGlass (ERCS)
Description: Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal
Study: NCT02552082

Intervention type: DEVICE
Intervention: Scorpio NRG posterior stabilized (PS)
Study: NCT01812603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
Study: NCT03692455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Description: The Roux-en-Y gastric bypass procedure involves creating a stomach pouch out of a small portion of the stomach and attaching it directly to the small intestine, bypassing a large part of the stomach and duodenum. Not only is the stomach pouch too small to hold large amounts of food, but by skipping the duodenum, fat absorption is substantially reduced.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical Sleeve Gastrectomy
Description: VSG surgery restricts food intake and decreases the amount of food used. Most of the stomach is removed during this surgery, which may decrease ghrelin, a hormone that prompts appetite. Lower amounts of ghrelin may reduce hunger more than other purely restrictive surgeries, such as AGB.
Study: NCT02207582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Prefrontal tRNS
Description: 2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Prefrontal tRNS
Description: 2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
Study: NCT03610217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension algorithm
Description: Patients diagnosed with pulmonary arterial hypertension secondary to systemic sclerosis will be randomized to receive anticoagulation (warfarin, rivaroxaban or apixaban)
Study: NCT00004856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study: NCT04052126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized physical activity program
Description: Participants who agreed to participate in the study will participate in an individualized 6-month physical activity (PA) program, consisting of 3 periods: initiation (1st month), transition (2nd-3rd months) and autonomy (4th-6th months). It is based on 4 PA modalities:~The supervised PA session in a sterile room or at home once a week during the initiation and transition phases (20-45 min, low-to-moderate intensity, walking, muscle strengthening, balance and flexibility exercises).~The unsupervised PA session in a sterile room or at home once a week during the transition phase and twice a week during the autonomy phase (same as supervised session).~Follow-up by telephone once a month during the autonomy phase (30 min, support to PA).~Continuously wearing an activity tracker throughout the entire program (promotion of walking).~Activities are planned over a period of 6 months to achieve an intervention that meets the key principles of progression, specificity and empowerment.
Study: NCT03610217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raynaud's phenomenon algorithm
Description: Patients with mild Raynaud's phenomenon not responding to the first line treatment (nifedipine), will be randomized to receive losartan or nifedipine plus atorvastatin or nifedipine plus losartan. If they fail the second line they will be crossed over to the other options randomly.~Patients with severe Raynaud's phenomenon not responding to the first line treatment (nifedipine) or failing the previous mild Raynaud's algorithm, will be randomized to receive nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital ulcer algorithm
Description: Patients with active digital ulcers not healing after 3 months or developing new ones with nifedipine will be randomized to nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option.~Patients who develop new digital ulcers under treatment with nifedipine will be randomized to nifedipine plus atorvastatin plus standard of care or nifedipine plus standard of care. If they fail the second line they will be crossed over to the other option.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inflammatory arthritis algorithm
Description: Patients with inflammatory arthritis failing methotrexate and/or prednisone and/or hydroxychloroquine and/or sulfasalazine will be randomized to receive intravenous rituximab or subcutaneous tocilizumab. If they fail the second line they will be crossed over to the other option.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux algorithm
Description: Patients with gastroesophageal reflux failing standard doses of proton pump inhibitors (PPI) will be randomized to receive double doses of PPI or standard dose of PPI plus ranitidine or double doses of PPI plus domperidone or double doses of PPI plus prucalopride/erythromycin. If they fail the second line they will be crossed over to the other options randomly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacterial overgrowth algorithm
Description: Patients with bacterial overgrowth will be randomized to receive erythromycin or metronidazole or amoxicillin. If they fail the second line they will be crossed over to the other options randomly.
Study: NCT04218487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuefu-Zhuyu Capsule
Description: treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.
Study: NCT02350257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT
Description: 12 weeks of internet-based CBT
Study: NCT03250117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole oral product
Description: oral immediate-release ropinirole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole oral product
Description: oral immediate-release ropinirole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole oral product
Description: oral immediate-release ropinirole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole oral product
Description: oral immediate-release ropinirole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole Implant
Description: ropinirole hydrochloride/ethylene vinyl acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole Implant
Description: ropinirole hydrochloride/ethylene vinyl acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole Implant
Description: ropinirole hydrochloride/ethylene vinyl acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole Implant
Description: ropinirole hydrochloride/ethylene vinyl acetate
Study: NCT04015024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028 150mg bid
Description: 150mg oral administration twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028 200mg bid
Description: 200mg oral administration twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028 300mg qd
Description: 300mg oral administration once a day
Study: NCT00238615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20 mg/m2, 75 mg/m2 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC of 2 and 6 infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: NEOADJUVANT RADIOTHERAPY Radiation therapy will be concurrent with the chemotherapy. Radiation therapy will begin within 24 hours of chemotherapy. CONSOLIDATION RADIOTHERAPY Patients with positive surgical margins or incomplete resection (tumor shaved from spine or great vessels) will receive an additional boost of radiotherapy 3 to 6 weeks after surgery. This will be a 16 Gy boost given with concurrent weekly chemotherapy as during the neoadjuvant period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: All patients will be taken to surgical excision, unless they have developed a condition other than progressive disease, which would make surgery unsafe.
Study: NCT02037854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrient formulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutrient formulation
Study: NCT01824576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITPR
Description: Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
Study: NCT01993940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Naldemedine 0.2 mg tablet taken orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally once a day
Study: NCT00363363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.